Microfluidic LNP Mixing Patents: Top Companies & Trends 2026
A data-led view of microfluidic LNP mixing patents: who leads, how filing activity has moved since 2017, which IPC classes are crowded and where device-layer claim space stays open.
Filing growth = 2021 (13 records) → 2024 (3); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 50 records in scope (CR5), not the ranked leaders only.
A concentrated field built on a handful of formulation patents
Microfluidic mixing is the manufacturing step that turns lipid and nucleic-acid components into stable lipid nanoparticles at controllable size and polydispersity, and it sits directly upstream of every mRNA and siRNA therapeutic that depends on LNP delivery. The 50 records in this dataset span 2015 through the current data cut-off, and the picture they show is one of early concentration: a single assignee holds the majority of filings, and the claim language that dominates is formulation and preparation-method language rather than mixing-hardware language.
That imbalance matters for anyone drafting new claims. The formulation layer, classified under A61K, is crowded and cited heavily by later filers. The physical apparatus layer that performs the mixing — chip geometry, channel design, real-time particle monitoring — is barely claimed at all in this corpus, which is the clearest sign of where a narrowly drafted device claim still has room to clear prior art.
Filing trends and technology composition
The dataset spans 50 published records from 2015 through the 2026-08-31 cut-off, giving a filing history long enough to separate a genuine activity peak from the reporting lag at the recent end.
Filings peaked in 2021, recent years still filling in
Annual filings rose from 4 in 2017 to a peak of 13 in 2021, then declined to 3 by 2024 — a documented -77% over that span. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are not yet complete and should not be read as a slowdown.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Formulation claims dominate; device claims are thin
All 50 records in scope carry an A61K medicinal-preparations classification, with therapeutic-activity (A61P, 8.0%) and small-molecule/genetic-engineering classes (C07C, C12N, each 4.0%) trailing well behind. Lab-apparatus classification (B01L) appears in just 1 record — 2.0% of the 50 — despite every method claim depending on a physical mixing apparatus.
Shares are the percentage of the 50 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lipid-Nanoparticle Delivery: Microfluidic LNP Mixing Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lipid-nanoparticle delivery: microfluidic lnp mixing patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe records other filers had to design around
US20230285297A1 — Methods of preparing lipid nanoparticles
The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and LNP formulations produced by using such methods. The present disclosure further provides therapeutic and diagnostic uses related to the produced LNP formulations.Filed by ModernaTX, Inc., published 2023-09-14. Its claim structure spans preparation method, product-by-process and downstream use, which is what gives it broad practical reach across the LNP manufacturing chain.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2017218704A1 | Stabilized formulations of lipid nanoparticles | 321 |
| 2 | WO2020061457A1 | Preparation of lipid nanoparticles and methods of administration thereof | 146 |
| 3 | WO2021155274A1 | Methods of preparing lipid nanoparticles | 88 |
| 4 | WO2020160397A1 | Methods of preparing lipid nanoparticles | 69 |
| 5 | US20210378980A1 | Preparation of lipid nanoparticles and methods of administration thereof | 62 |
| 6 | US20220062175A1 | Methods of preparing lipid nanoparticles | 50 |
| 7 | EP3468537A1 | Stabilized formulations of lipid nanoparticles | 9 |
| 8 | US20230285297A1 | Methods of preparing lipid nanoparticles | 7 |
| 9 | US20230157955A1 | Vesicle compositions for oral delivery | 7 |
| 10 | CA3128215A1 | Methods of preparing lipid nanoparticles | 5 |
Citation counts are drawn from within this searched corpus and favour older records; use them as a signal of influence on later filings, not a measure of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say before you file
Three figures from this dataset matter more than the rest for deciding where to file, who to watch and what remains open.
A small group controls most of the field
The leading assignee alone holds 35 of the 50 records in scope, and together the top 5 hold 86.0% of all records. The ranking runs to 15 companies total, but from fifth place onward the counts drop sharply — fifth place holds 2 records, tenth place just 1.
Past its peak, but recent years are incomplete
Filings rose to a peak of 13 in 2021 then fell to 3 by 2024. Publication lags filing by roughly 18 months, so 2025-2026 counts in this dataset are not yet complete and should not be read as evidence the field is still cooling.
Device-layer claims are thin
Every record in scope touches A61K medicinal preparations, but only 1 record carries a B01L lab-apparatus classification. Formulation chemistry is heavily claimed; the physical mixing hardware underneath it is comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lipid-nanoparticle delivery: microfluidic lnp mixing patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Shenzhen Jinlin Biotechnology Co., Ltd. | INST OF CHEM | 2 |
| ModernaTX, Inc. | SMITH MIKE | 1 |
| ModernaTX, Inc. | SKINNER BRIE | 1 |
| ModernaTX, Inc. | AUER JASON | 1 |
Co-assignment is rare in this dataset — 4 co-assignee pairs across 50 records, the strongest pairing a Chinese biotech with an academic chemistry institute, and two further pairs linking Moderna's corporate entity with named individual inventors.
Where to take this analysis
The figures above establish concentration and trend. The next layer of work is claim-level: reading the top-cited filings against a specific process or device design.
Check freedom to operate against the leader's portfolio
With one assignee holding 35 of 50 records and the top 5 controlling 86.0% of the field, any new filing or product launch should start by mapping its process steps against that leader's granted claims.
Run a claim comparison in EurekaEvaluate the device-layer white space
Lab-apparatus classification (B01L) covers only 1 of the 50 records. A chip- or channel-level claim drafted around specific geometry and monitoring hardware has comparatively little prior art to clear.
Explore white space mapping in EurekaTrack filings past the 2024 cut-off
Publication lags filing by roughly 18 months, so 2025-2026 activity in this dataset is still incomplete. Set an alert to catch newly published filings as they land.
Set up monitoring in EurekaCommon questions about microfluidic LNP mixing patents
The assignee ranking covers 15 companies, and it is heavily concentrated: the leading filer alone accounts for 35 of the 50 records in scope, and the top 5 combined hold 86.0% of all 50 records. That leaves a long tail — the tenth-ranked filer holds just 1 record — so most named organisations in this space are single-filing entrants rather than repeat filers. Anyone assessing freedom to operate should treat the leader's portfolio as the primary block to clear before looking at the rest of the field.
Filing activity peaked in 2021 at 13 records and had fallen to 3 by 2024, a -77% change over that three-year window using the figures in this dataset. However, publication lags filing by roughly 18 months, so 2025 and 2026 counts are structurally incomplete and cannot yet be read as a genuine decline. The safest reading is that the field is past its documented peak filing year but current-year activity is still being reported.
Every record in scope carries an A61K medicinal-preparations classification, which is the anchor class for this search. Smaller shares fall under A61P therapeutic activity (8.0% of the 50 records), C07C and C12N (4.0% each), and single-record classes including B01L lab apparatus, C07K peptides, and C12P fermentation, each at 2.0%. Because a single record can carry several classes, these shares add up to more than 100% and should not be summed as if they were mutually exclusive.
WO2017218704A1, titled Stabilized formulations of lipid nanoparticles, carries 321 citations in this dataset — well ahead of the second most-cited record, WO2020061457A1, at 146. High citation counts inside a searched corpus tend to favour older records simply because they have had more time to be cited, so treat this as a signal of influence on subsequent filings rather than a claim about current technical importance. Both of the two most-cited records concern LNP formulation and preparation methods rather than mixing hardware itself.
The receiving-office data shows WIPO/PCT filings (11) and US filings (8) carrying the most volume, with Europe (7) close behind; Canada (5) and Australia (3) show comparatively lower filing counts. Technology-wise, the lab-apparatus classification B01L holds only 1 of the 50 records, meaning device- and chip-level claims are far less contested than the formulation claims that sit under A61K. A new entrant focused on mixing hardware rather than formulation chemistry, and filing through a lower-volume receiving office, faces measurably less prior art to clear.
Research Lipid-Nanoparticle Delivery: Microfluidic LNP Mixing Patent Landscape in depth with Eureka
Go past this page: query the whole lipid-nanoparticle delivery: microfluidic lnp mixing patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.